Gene · 6607
SMN2: survival of motor neuron 2, centromeric
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SMN2: survival of motor neuron 2, centromeric. Genes, record 6607. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6607
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16637 | Survival motor neuron protein | 294 | 15 | Ensembl, GeneID, HGNC |
Source UniProt
Patents140
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026086420 A | 2026-05-26 | 33 | Q16637 | Espacenet |
| EP 4704920 A1 | 2026-03-11 | 137 | Q16637 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 65920 | Q16637 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 65927 | Q16637 | Espacenet |
| US 12478692 B2 | 2025-11-25 | 3 | Q16637 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10364 | Q16637 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4377 | Q16637 | Espacenet |
| EP 4585229 A2 | 2025-07-16 | 2 | Q16637 | Espacenet |
| EP 4585263 A2 | 2025-07-16 | 2 | Q16637 | Espacenet |
| US 12350311 B2 | 2025-07-08 | 2 | Q16637 | Espacenet |
1 to 10 of 140
See all 140 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| NUSINERSEN | CHEMBL3301572 | SMN2 pre-mRNA positive modulator | POSITIVE MODULATOR | ChEMBL |
| NUSINERSEN SODIUM | CHEMBL3833342 | SMN2 pre-mRNA positive modulator | POSITIVE MODULATOR | ChEMBL |
| ONASEMNOGENE ABEPARVOVEC | CHEMBL4297240 | Survival motor neuron protein exogenous gene | EXOGENOUS GENE | ChEMBL |
| RISDIPLAM | CHEMBL4297528 | SMN2 pre-mRNA positive modulator | POSITIVE MODULATOR | ChEMBL |
Trials54
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07444450 | ONASEMNOGENE ABEPARVOVEC | PHASE3 | ClinicalTrials.gov | |
| NCT07070999 | RISDIPLAM | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07047144 | NUSINERSEN | PHASE2 | ClinicalTrials.gov | |
| NCT07047144 | RISDIPLAM | PHASE2 | ClinicalTrials.gov | |
| NCT06555419 | NUSINERSEN | PHASE1 | ClinicalTrials.gov | |
| NCT05861999 | RISDIPLAM | PHASE4 | ClinicalTrials.gov | |
| NCT05861986 | RISDIPLAM | PHASE4 | ClinicalTrials.gov | |
| NCT05808764 | RISDIPLAM | PHASE2 | ClinicalTrials.gov | |
| NCT05769465 | NUSINERSEN | ClinicalTrials.gov | ||
| NCT05769465 | ONASEMNOGENE ABEPARVOVEC | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsNIH grants1,484
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SMN2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA045508 | CSHL Cancer Center Support Grant | 16 | 2025 |
| R01GM042699 | Biochemistry of Pre-mRNA Splicing | 16 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 10 | 2025 |
| P20GM103446 | Delaware INBRE | 9 | 2025 |
| R01NS102451 | RNA-Mediated Mechanisms of Motor System Dysfunction in Spinal Muscular Atrophy | 9 | 2025 |
| R01NS078375 | Mechanisms of Central Synaptic Dysfunction in SMA | 8 | 2025 |
| R35GM118103 | Recognition of Cellular Targets by single and double-stranded nucleic acids | 7 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 6 | 2025 |
| R35NS122306 | Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies | 6 | 2025 |
| R01CA249180 | Targeted degradation of RNAs by using small molecules | 5 | 2025 |
1 to 10 of 1,484Source NIH's project files
See all 1,484 nih grantsPapers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The utilization of multiplex PCR with fragment analysis for carrier screening of spinal muscular atrophy. | Clin Chim Acta | 2027 | 42551705 | PubTator, text mining | PubMed |
| Clinical Practice of Single-Molecule Real-Time Sequencing in the Diagnosis of Spinal Muscular Atrophy. | Mol Genet Genomic Med | 2026 | 42827317 | PubTator, text mining | PubMed |
| Muscle biopsy to end a diagnostic odyssey in a genetically complex case of spinal muscular atrophy type 3: the importance of "old school" in the next-generation sequencing era. | Eur J Paediatr Neurol | 2026 | 42826493 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy. | Continuum (Minneap Minn) | 2026 | 42825550 | PubTator, text mining | PubMed |
| Unbiased bioinformatic and clinical analysis identifies glial fibrillary acidic protein as a potential biomarker in spinal muscular atrophy. | Brain Commun | 2026 | 42798874 | PubTator, text mining | PubMed |
| Intensive Family-Centered Rehabilitation and Motor Outcomes in a Child with Global Developmental Delay: A Case Report. | Children (Basel) | 2026 | 42794238 | PubTator, text mining | PubMed |
| Comparative Analysis of SMN2 Splicing Activity and Protein Production Following In Vitro Treatment with the Generic Risdiplam Drug Vapromin® and the Reference Drug Evrysdi®. | Biomedicines | 2026 | 42792736 | PubTator, text mining | PubMed |
| Pharmacovigilance and network toxicology analysis of risdiplam-associated adverse events in pediatric patients with spinal muscular atrophy. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42789045 | PubTator, text mining | PubMed |
| Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. | Expert Rev Mol Med | 2026 | 42776081 | PubTator, text mining | PubMed |
| Case Report: Presymptomatic risdiplam in preterm monozygotic twins with co-occurring spinal muscular atrophy and tuberous sclerosis complex. | Front Genet | 2026 | 42764968 | PubTator, text mining | PubMed |
1 to 10 of 3,510
See all 3,510 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6607
GET https://conductscience.org/api/genes/v1/6607/patents?page=2